1
|
Puls JS, Winnerling B, Power JJ, Krüger AM, Brajtenbach D, Johnson M, Bilici K, Camus L, Fließwasser T, Schneider T, Sahl HG, Ghosal D, Kubitscheck U, Heilbronner S, Grein F. Staphylococcus epidermidis bacteriocin A37 kills natural competitors with a unique mechanism of action. ISME J 2024; 18:wrae044. [PMID: 38470311 PMCID: PMC10988021 DOI: 10.1093/ismejo/wrae044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/23/2024] [Revised: 03/01/2024] [Accepted: 03/11/2024] [Indexed: 03/13/2024]
Abstract
Many bacteria produce antimicrobial compounds such as lantibiotics to gain advantage in the competitive natural environments of microbiomes. Epilancins constitute an until now underexplored family of lantibiotics with an unknown ecological role and unresolved mode of action. We discovered production of an epilancin in the nasal isolate Staphylococcus epidermidis A37. Using bioinformatic tools, we found that epilancins are frequently encoded within staphylococcal genomes, highlighting their ecological relevance. We demonstrate that production of epilancin A37 contributes to Staphylococcus epidermidis competition specifically against natural corynebacterial competitors. Combining microbiological approaches with quantitative in vivo and in vitro fluorescence microscopy and cryo-electron tomography, we show that A37 enters the corynebacterial cytoplasm through a partially transmembrane-potential-driven uptake without impairing the cell membrane function. Upon intracellular aggregation, A37 induces the formation of intracellular membrane vesicles, which are heavily loaded with the compound and are essential for the antibacterial activity of the epilancin. Our work sheds light on the ecological role of epilancins for staphylococci mediated by a mode of action previously unknown for lantibiotics.
Collapse
Affiliation(s)
- Jan-Samuel Puls
- Institute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, 53115 Bonn, Germany
| | - Benjamin Winnerling
- Institute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, 53115 Bonn, Germany
- German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53115 Bonn, Germany
| | - Jeffrey J Power
- Interfaculty Institute of Microbiology and Infection Medicine, Department of Infection Biology, University of Tübingen, 72076 Tübingen, Germany
| | - Annika M Krüger
- Clausius Institute of Physical and Theoretical Chemistry, University of Bonn, 53115 Bonn, Germany
| | - Dominik Brajtenbach
- Clausius Institute of Physical and Theoretical Chemistry, University of Bonn, 53115 Bonn, Germany
| | - Matthew Johnson
- Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia
- ARC Centre for Cryo-electron Microscopy of Membrane Proteins, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, VIC 3010, Australia
| | - Kevser Bilici
- Interfaculty Institute of Microbiology and Infection Medicine, Department of Infection Biology, University of Tübingen, 72076 Tübingen, Germany
| | - Laura Camus
- Interfaculty Institute of Microbiology and Infection Medicine, Department of Infection Biology, University of Tübingen, 72076 Tübingen, Germany
| | - Thomas Fließwasser
- Institute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, 53115 Bonn, Germany
- German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53115 Bonn, Germany
| | - Tanja Schneider
- Institute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, 53115 Bonn, Germany
- German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53115 Bonn, Germany
| | - Hans-Georg Sahl
- Institute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, 53115 Bonn, Germany
| | - Debnath Ghosal
- Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia
- ARC Centre for Cryo-electron Microscopy of Membrane Proteins, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, VIC 3010, Australia
| | - Ulrich Kubitscheck
- Clausius Institute of Physical and Theoretical Chemistry, University of Bonn, 53115 Bonn, Germany
| | - Simon Heilbronner
- Interfaculty Institute of Microbiology and Infection Medicine, Department of Infection Biology, University of Tübingen, 72076 Tübingen, Germany
- German Centre for Infection Research (DZIF), Partner Site Tübingen, 72076 Tübingen, Germany
- Present address: Faculty of Biology, Microbiology, Ludwig-Maximilians-University of Munich, 82152 München, Germany
| | - Fabian Grein
- Institute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, 53115 Bonn, Germany
- German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53115 Bonn, Germany
| |
Collapse
|
2
|
Sternkopf M, Nagy M, Baaten CCFMJ, Kuijpers MJE, Tullemans BME, Wirth J, Theelen W, Mastenbroek TG, Lehrke M, Winnerling B, Baerts L, Marx N, De Meester I, Döring Y, Cosemans JMEM, Daiber A, Steven S, Jankowski J, Heemskerk JWM, Noels H. Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions. Arterioscler Thromb Vasc Biol 2020; 40:e65-e77. [PMID: 31893947 DOI: 10.1161/atvbaha.119.313645] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
OBJECTIVE In patients with diabetes mellitus, increased platelet reactivity predicts cardiac events. Limited evidence suggests that DPP-4 (dipeptidyl peptidase 4) influences platelets via GLP-1 (glucagon-like peptide 1)-dependent effects. Because DPP-4 inhibitors are frequently used in diabetes mellitus to improve the GLP-1-regulated glucose metabolism, we characterized the role of DPP-4 inhibition and of native intact versus DPP-4-cleaved GLP-1 on flow-dependent thrombus formation in mouse and human blood. Approach and Results: An ex vivo whole blood microfluidics model was applied to approach in vivo thrombosis and study collagen-dependent platelet adhesion, activation, and thrombus formation under shear-flow conditions by multiparameter analyses. In mice, in vivo inhibition or genetic deficiency of DPP-4 (Dpp4-/-), but not of GLP-1-receptors (Glp1r-/-), suppressed flow-dependent platelet aggregation. In human blood, GLP-1(7-36), but not DPP-4-cleaved GLP-1(9-36), reduced thrombus volume by 32% and impaired whole blood thrombus formation at both low/venous and high/arterial wall-shear rates. These effects were enforced upon ADP costimulation and occurred independently of plasma factors and leukocytes. Human platelets did not contain detectable levels of GLP-1-receptor transcripts. Also, GLP-1(7-36) did not inhibit collagen-induced aggregation under conditions of stirring or stasis of platelets, pointing to a marked flow-dependent role. CONCLUSIONS Native, intact GLP-1 is a natural suppressor of thrombus growth under physiological flow conditions, with DPP-4 inhibition and increased intact GLP-1 suppressing platelet aggregation under flow without a main relevance of GLP-1-receptor on platelets.
Collapse
Affiliation(s)
- Marieke Sternkopf
- From the Institute for Molecular Cardiovascular Research (IMCAR) (M.S., C.C.F.M.J.B., J.W., W.T., B.W., J.J., H.N.), University Clinic Aachen, Germany
| | - Magdolna Nagy
- Department of Biochemistry (M.N., M.J.E.K., B.M.E.T., T.G.M., J.M.E.M.C., J.W.M.H.), Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, The Netherlands
| | - Constance C F M J Baaten
- From the Institute for Molecular Cardiovascular Research (IMCAR) (M.S., C.C.F.M.J.B., J.W., W.T., B.W., J.J., H.N.), University Clinic Aachen, Germany
| | - Marijke J E Kuijpers
- Department of Biochemistry (M.N., M.J.E.K., B.M.E.T., T.G.M., J.M.E.M.C., J.W.M.H.), Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, The Netherlands
| | - Bibian M E Tullemans
- Department of Biochemistry (M.N., M.J.E.K., B.M.E.T., T.G.M., J.M.E.M.C., J.W.M.H.), Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, The Netherlands
| | - Julia Wirth
- From the Institute for Molecular Cardiovascular Research (IMCAR) (M.S., C.C.F.M.J.B., J.W., W.T., B.W., J.J., H.N.), University Clinic Aachen, Germany
| | - Wendy Theelen
- From the Institute for Molecular Cardiovascular Research (IMCAR) (M.S., C.C.F.M.J.B., J.W., W.T., B.W., J.J., H.N.), University Clinic Aachen, Germany
| | - Tom G Mastenbroek
- Department of Biochemistry (M.N., M.J.E.K., B.M.E.T., T.G.M., J.M.E.M.C., J.W.M.H.), Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, The Netherlands
| | - Michael Lehrke
- Medical Clinic I (M.L., N.M.), University Clinic Aachen, Germany
| | - Benjamin Winnerling
- From the Institute for Molecular Cardiovascular Research (IMCAR) (M.S., C.C.F.M.J.B., J.W., W.T., B.W., J.J., H.N.), University Clinic Aachen, Germany
| | - Lesley Baerts
- Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences, University of Antwerp, Belgium (L.B., I.D.M.)
| | - Nikolaus Marx
- Medical Clinic I (M.L., N.M.), University Clinic Aachen, Germany
| | - Ingrid De Meester
- Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences, University of Antwerp, Belgium (L.B., I.D.M.)
| | - Yvonne Döring
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University (LMU), Munich, Germany (Y.D.).,German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Germany (Y.D.).,Division of Angiology, Swiss Cardiovascular Centre, Inselspital, Bern University Hospital, University of Bern, Switzerland (Y.D.)
| | - Judith M E M Cosemans
- Department of Biochemistry (M.N., M.J.E.K., B.M.E.T., T.G.M., J.M.E.M.C., J.W.M.H.), Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, The Netherlands
| | - Andreas Daiber
- Center for Cardiology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany (A.D., S.S.)
| | - Sebastian Steven
- Center for Cardiology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany (A.D., S.S.)
| | - Joachim Jankowski
- From the Institute for Molecular Cardiovascular Research (IMCAR) (M.S., C.C.F.M.J.B., J.W., W.T., B.W., J.J., H.N.), University Clinic Aachen, Germany.,Experimental Vascular Pathology (J.J.), Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, The Netherlands
| | - Johan W M Heemskerk
- Department of Biochemistry (M.N., M.J.E.K., B.M.E.T., T.G.M., J.M.E.M.C., J.W.M.H.), Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, The Netherlands
| | - Heidi Noels
- From the Institute for Molecular Cardiovascular Research (IMCAR) (M.S., C.C.F.M.J.B., J.W., W.T., B.W., J.J., H.N.), University Clinic Aachen, Germany
| |
Collapse
|